138.70
전일 마감가:
$137.00
열려 있는:
$137.87
하루 거래량:
96,272
Relative Volume:
0.11
시가총액:
$13.75B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
47.02
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+1.04%
1개월 성능:
-3.73%
6개월 성능:
+58.13%
1년 성능:
+23.97%
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NBIX
Neurocrine Biosciences Inc
|
138.65 | 13.59B | 2.41B | 305.80M | 492.20M | 2.95 |
![]()
ZTS
Zoetis Inc
|
144.66 | 63.27B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 45.67B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.095 | 39.27B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.30 | 23.02B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
446.01 | 20.66B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-21 | 개시 | Truist | Buy |
2025-07-10 | 개시 | Goldman | Buy |
2025-04-15 | 업그레이드 | Needham | Hold → Buy |
2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2025-02-11 | 개시 | Deutsche Bank | Hold |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | 재개 | Citigroup | Neutral |
2023-12-12 | 개시 | Deutsche Bank | Buy |
2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
2023-08-21 | 재확인 | Mizuho | Neutral |
2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-10-11 | 개시 | UBS | Buy |
2022-09-26 | 개시 | Wells Fargo | Equal Weight |
2022-06-06 | 재개 | Jefferies | Buy |
2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2021-11-19 | 개시 | BMO Capital Markets | Underperform |
2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-09-23 | 재개 | Needham | Hold |
2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
2021-05-18 | 재개 | Goldman | Neutral |
2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
2021-02-02 | 개시 | Raymond James | Outperform |
2020-09-30 | 개시 | The Benchmark Company | Hold |
2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
2020-06-09 | 개시 | Wedbush | Outperform |
2020-03-06 | 개시 | Citigroup | Buy |
2020-02-27 | 개시 | Barclays | Equal Weight |
2020-02-24 | 개시 | William Blair | Outperform |
2020-02-06 | 개시 | Mizuho | Neutral |
2020-02-05 | 재확인 | H.C. Wainwright | Buy |
2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
2019-07-16 | 개시 | Oppenheimer | Outperform |
2019-06-05 | 개시 | Guggenheim | Neutral |
2019-05-21 | 개시 | Credit Suisse | Outperform |
2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-04-12 | 개시 | Evercore ISI | Outperform |
2019-02-06 | 재확인 | BofA/Merrill | Buy |
2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-12-13 | 개시 | Goldman | Buy |
2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - The AI Journal
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com India
Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com
Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PR Newswire
Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com
What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st
Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfolios2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail
Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st
Can Neurocrine Biosciences Inc. stock maintain growth trajectoryPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Will breakout in Neurocrine Biosciences Inc. lead to full recoveryRate Cut & Safe Entry Point Identification - newser.com
Should I buy Neurocrine Biosciences Inc. (NB3) stock before earnings seasonWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionCEO Change & Long-Term Safe Investment Plans - newser.com
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors - Business Wire
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
자본화:
|
볼륨(24시간):